Merck COX-2 Cardiovascular Safety Studies Will Enroll 30,000 Subjects

Merck plans to enroll approximately 30,000 subjects in cardiovascular safety trials to resolve issues raised about the CV effects of its COX-2 inhibitors Vioxx (rofecoxib) and Arcoxia (etoricoxib)